Evusheld Prescriber Checklist

Evusheld (long-acting monoclonal antibodies tixagevimab with cilgavimab) is authorized as pre-exposure prophylaxis for COVID-19. Evusheld is not a substitute for COVID-19 vaccination. For more information on Evusheld and other outpatient COVID-19 therapeutics, visit nyc.gov/health/covidprovidertreatments.

Review Eligibility

Evusheld should not be used in unvaccinated individuals for whom COVID-19 vaccination is recommended and who are anticipated to have an adequate response.

Evusheld is authorized for people who meet all the following criteria:

- Age 12 or older
- Weight of 88 pounds (40 kilograms) or greater
- Not currently infected with SARS-CoV-2
- No recent known exposure to COVID-19
- Have moderate to severe immune compromise (see below) or not recommended to get a COVID-19 vaccination due to a history of severe adverse reaction to a COVID-19 vaccine or any of its components

See the Fact Sheet for Healthcare Providers for more information: fda.gov/media/154701/download.

Assess for Immunocompromising Conditions or Treatments

Examples of medical conditions or treatments that may result in moderate to severe immune compromise include:

- Active treatment for solid tumors or hematologic malignancies
- Immunosuppressive therapy after solid-organ transplantation
- Having received chimeric antigen receptor T-cell therapy or a hematopoietic stem cell transplant, and being within two years of transplantation or taking immunosuppressive therapy
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome or Wiskott-Aldrich syndrome)
- Advanced or untreated HIV (CD4 count less than 200, history of AIDS-defining illness without immune reconstitution, or symptomatic HIV)
- Active treatment with high-dose corticosteroids (20 milligrams (mg) or more per day prednisone or equivalent for two weeks or more) alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis factor blockers or other immunosuppressive or immunomodulatory biologic agents (such as B cell depleting agents)
Assess COVID-19 Vaccination Status

Evusheld is not a substitute for vaccination in people for whom vaccination is recommended.

☑ Review patient’s COVID-19 vaccination history.
☑ Unless they have contraindications to COVID-19 vaccination, ensure they are up to date. Visit bit.ly/3JJYVqN to see the CDC’s Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised.
☑ Evusheld should be administered at least two weeks after COVID-19 vaccination.

Review Information with Patients or Caregivers Prior to Administration

☑ Communicate information consistent with the EUA Fact Sheet for Patients, Parents, and Caregivers (available at fda.gov/media/154702/download) and provide a physical or electronic copy of the fact sheet to the patient or caregiver.

☑ For patients with cardiac risk factors or a history of cardiac disease:
  • Inform them that a higher proportion of study participants who received Evusheld versus placebo (0.6% vs. 0.2%) reported rare but serious adverse cardiovascular events (myocardial infarctions and heart failure).
  • Advise them to seek immediate medical attention if they experience symptoms suggestive of a cardiovascular event.

Prescribe Evusheld

☑ Specify the dose of each product in the prescription:
  • The first dose is now 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular (IM) injections.
  • For patients who received the previously recommended dose (150 mg of tixagevimab and 150 mg of cilgavimab), administer a second dose (150 mg of tixagevimab and 150 mg of cilgavimab) as soon as possible.

☑ The recommended timing for repeat dosing is currently every six months.

☑ Order Evusheld according to your organization’s policies or go to the COVID-19 Therapeutics Locator at covid-19-therapeutics-locator-dhhs.hub.arcgis.com to find facilities and pharmacies with Evusheld in stock.

☑ For more information about accessing Evusheld in NYC, including delivery to your practice via Alto Pharmacy or referring patients to NYC Health and Hospitals, visit nyc.gov/health/covidprovidertreatments.

The NYC Health Department may change recommendations as the situation evolves. 4.5.22